Relationship Between Estrogen Treatment and Skeletal Health in Women With Cystic Fibrosis

• Published in: The American journal of the medical sciences Vol. 360; no. 5; p. 581
• Main Authors: Wu, Malinda, Bettermann, Erika L, Arora, Neha, Hunt, William R, McCracken, Courtney, Tangpricha, Vin
• Format: Journal Article
• Language: English
• Published: United States 01.11.2020
• Subjects: Adolescent; Adult; Bone Density - drug effects; Bone Density - physiology; Cohort Studies; Cystic Fibrosis - blood; Cystic Fibrosis - diagnostic imaging; Cystic Fibrosis - drug therapy; Estradiol - pharmacology; Estradiol - therapeutic use; Female; Humans; Retrospective Studies; Treatment Outcome; Vitamin D - blood; Young Adult; Women's Health/statistics and numerical data; Vitamin D; Hypogonadism/drug therapy; Estradiol; Adolescent
• ISSN: 1538-2990
• DOI: 10.1016/j.amjms.2020.06.005

Patients with cystic fibrosis (CF) are at risk for CF-related bone disease. Women with CF may use estrogen supplementation for reasons other than skeletal health. It is unknown whether estrogen therapy has a beneficial impact on skeletal health in women with CF. In this retrospective cohort study of women with CF followed at a single CF center, the lumbar spine bone mineral density (BMD) of women with CF exposed to supplemental and not exposed to supplemental estrogen were compared. Spline function models included the main effect of estrogen exposure and the interaction between age and estrogen supplementation. Of the 145 subjects analyzed, 44 subjects were exposed to supplemental estrogen. The baseline characteristics of estrogen exposed and unexposed subjects were similar except for use of CF transmembrane conductance regulator modulators and anti-osteoporosis medications. Women exposed to estrogen reached peak BMD around 21 years of age, but women not exposed to estrogen reached peak BMD around 25 years of age. A significant interaction of age and estrogen supplementation indicated that the lumbar spine BMD trajectories differed by exposure group. Our study demonstrates that few women with CF of reproductive age are prescribed estrogen therapy. Furthermore, estrogen exposure up to age 21 is associated with improved BMD, but estrogen exposure after age 21 does not appear to be associated with improved BMD. Further studies are needed to understand the reasons for the low rates of estrogen use in young women with CF and the optimal timing, dose and formulation of estrogen prescription.